Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.

被引：1
|
作者：
Advani, R
Maeda, L
Hoppe, RT
Breslin, S
Rosenberg, SA
Baer, D
Mason, J
Horning, SJ
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] No Calif Kaiser Permanente, Oakland, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1932.1932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1932
引用
收藏
页码：548A / 548A
页数：1
相关论文
共 50 条
  • [21] Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial.
    Radford, J
    Williams, MV
    Hancock, BW
    Hoskin, P
    Sun-Mynt, H
    Smith, P
    Qian, W
    Linch, D
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [22] Outcome of patients progressing or relapsing after primary treatment with two cycles of chemotherapy and radiotherapy for early stage (favorable) Hodgkin's disease.
    Josting, A
    Franklin, J
    Sieniawski, M
    Pfistner, B
    Schober, T
    Nisters-Backes, H
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 241A - 241A
  • [23] Invited presentation from ASTRO: Randomized trial in the treatment of early stage Hodgkin's disease (ESHD) using radiotherapy (RT) alone versus combined modality treatment (CMT)
    Sehlen, S
    RADIOLOGY, 1999, 213P : 324 - 324
  • [24] Elderly patients with early-unfavorable stage Hodgkin's disease (HD) have a poorer outcome when treated with combined modality treatment and extended field radiotherapy (EF): A retrospective analysis of the German Hodgkin study group.
    Engert, A
    Haverkamp, H
    Eich, HT
    Josting, A
    Pfistner, B
    Diehl, V
    BLOOD, 2004, 104 (11) : 368A - 368A
  • [25] Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD)
    Petrakova, K
    Koukalová, H
    Soumarová, R
    Palácov, M
    Blazkova, S
    Vyzula, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 606S - 606S
  • [26] COMBINED VBM (VINBLASTINE, BLEOMYCIN, METHOTREXATE) CHEMOTHERAPY AND INVOLVED FIELD (IF) RADIOTHERAPY (RT) IN EARLY STAGE HODGKIN'S LYMPHOMA (HL): A SINGLE CENTRE EXPERIENCE
    Cocorocchio, E.
    Bassi, S.
    Negri, M.
    Peccatori, F. A.
    Travaini, L. L.
    Piperno, G.
    Preda, L.
    Pruneri, G.
    Vanazzi, A.
    Alietti, A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 631 - 632
  • [27] Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease
    Pavlovsky, S
    Schvartzman, E
    Lastiri, F
    Magnasco, H
    Corrado, C
    Raslawski, E
    Cancela, MEA
    Ardaiz, MC
    Cerutti, I
    Rosso, A
    Bruno, S
    Aranguren, PN
    Salvarezza, A
    Donato, H
    Dibar, E
    Zirone, S
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2652 - 2658
  • [28] Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease
    Lorusso, V
    Timurian, A
    Brandi, M
    Pellecchia, A
    Cramarossa, A
    Marzullo, F
    deLena, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (04) : 669 - 674
  • [29] Stanford V (SV) versus ABVD for adult patients with advanced Hodgkin's disease (HD): Preliminary results of a randomized phase II trial from the BNLI.
    Sweetenham, J
    Smith, P
    MacMillan, A
    Cunningham, D
    Hoskin, P
    Horwich, A
    Linch, D
    BLOOD, 2000, 96 (11) : 249B - 249B
  • [30] Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial
    Engert, Andreas
    Franklin, Jeremy
    Eich, Hans Theodor
    Brillant, Corinne
    Sehlen, Susanne
    Cartoni, Claudio
    Herrmann, Richard
    Pfreundschuh, Michael
    Sieber, Markus
    Tesch, Hans
    Franke, Astrid
    Koch, Peter
    de Wit, Maike
    Paulus, Ursula
    Hasenclever, Dirk
    Loeffler, Markus
    Mueller, Rolf-Peter
    Mueller-Hermelink, Hans Konrad
    Duehmke, Eckhart
    Diehl, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3495 - 3502
12345